Novo Nordisk shares dive 9% after heart medicine fails trial

Shares of Novo Nordisk nosedived as much as 10% after the drugmaker said a late-stage heart drug trial failed to reduce major cardiovascular events compared to placebo.This is breaking news. Please refresh for updates.